Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study
about
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsXpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsIntegrated therapy for HIV and tuberculosisA microbiological revolution meets an ancient disease: improving the management of tuberculosis with genomicsPoint-of-care diagnosis of tuberculosis: past, present and futureEvaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic reviewThe impact and cost of scaling up GeneXpert MTB/RIF in South AfricaPopulation health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluationTime to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South AfricaCorrelation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility resultsERAIZDA: a model for holistic annotation of animal infectious and zoonotic diseasesThe future of molecular diagnostics for drug-resistant tuberculosis.Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda.Performance of Xpert MTB/RIF in the diagnosis of tuberculous mediastinal lymphadenopathy by endobronchial ultrasound.Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes.Retrospective observational study of diagnostic accuracy of the Xpert® MTB/RIF assay on fiberoptic bronchoscopy sampling for early diagnosis of smear-negative or sputum-scarce patients with suspected tuberculosisAssessment of the genotype MTBDRplus assay for rifampin and isoniazid resistance detection on sputum samples in Cote d'Ivoire.Evaluation of microscopic observation drug susceptibility assay for diagnosis of multidrug-resistant tuberculosis in Viet Nam.Molecular oncology testing in resource-limited settings.A diagnostic accuracy study of Xpert®MTB/RIF in HIV-positive patients with high clinical suspicion of pulmonary tuberculosis in Lima, Peru.Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis.Diagnostic accuracy and turnaround time of the Xpert MTB/RIF assay in routine clinical practiceGeneXpert--a game-changer for tuberculosis control?Evaluation of FLASH - PCR forrapid detection of Mycobacterium tuberculosis from clinical specimens.A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan AfricaScaling up multidrug-resistant tuberculosis care in ChinaComparison of Xpert MTB/RIF Assay and the Conventional Sputum Microscopy in Detecting Mycobacterium tuberculosis in Northern Thailand.A High Burden Human Immunodeficiency Virus and Tuberculosis Resource Limited Setting, Gains from Including Xpert MTB/RIF in the Diagnostic Algorithm of Fluid Specimens Submitted for Exclusion of Lymphoma by Immunophenotypic Analysis.Respiratory Infections in the U.S. Military: Recent Experience and ControlXpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility.Performance of the Roche LightCycler real-time PCR assay for diagnosing extrapulmonary tuberculosis.Pulmonary immune-compartment-specific interferon gamma responses in HIV-infected individuals with active tuberculosis (TB) in an area of high TB prevalence.The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosisPerformance of the G4 Xpert® MTB/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: a retrospective case-control study of analytical and clinical samples from high- and low-tuberculosis prevalence settingsPredictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa.Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa.Diagnostic accuracy of the genotype MTBDRsl assay for rapid diagnosis of extensively drug-resistant tuberculosis in HIV-coinfected patientsDiagnostic Accuracy of Xpert Test in Tuberculosis Detection: A Systematic Review and Meta-analysis.Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care testEmpirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial
P2860
Q24200879-D8ECAACA-92DD-4C68-8C0F-182FBD42CEE6Q24201466-CA0A29A6-E727-4EFF-BC14-37FFD3AB8863Q26749428-0AF443B4-E013-48FD-AAAA-386F7E4349F9Q26999868-F0045E3C-6151-4558-9B57-9D48D2EC9277Q27004667-31C7B14F-2651-4E69-BA1A-C92FD816F8FBQ28481845-312A7FD6-2624-4667-8D13-2558149073ADQ28484044-4781A519-4643-4F50-8BAE-F8B601FF166FQ28485280-C2AA05C1-7458-4F16-9C41-DE716027D2E9Q28533713-C3F1FB72-8435-4071-A8DC-173FA546A27EQ28540488-6B04DFA7-683E-4BC1-8052-A05DF2A49EE1Q28607278-3C5D599A-8D79-4C30-A46A-E313F75F75E3Q30455525-A6657AE3-E282-4247-8774-EFB99CC7F7C0Q31106576-4782454D-1BAF-4FED-81C1-B9BDC00CF0F4Q33640495-9BCCCB1F-89B9-4263-BDB0-6489B66CAA64Q33900005-1C9EE778-B298-411B-9B75-B4807B5E7325Q34062760-7CFD47C4-38B3-4531-8F9F-4E7F13F1FA47Q34162862-83906030-7961-4BFB-8BA1-A40E5F821D4BQ34178450-6BEE64A7-69AD-4215-A071-2626582A6FFEQ34409732-F36AF440-7502-4CC2-9AD8-6B5A04FBEE37Q34412632-7B51F487-8031-4C1B-96E3-B06FEA3CCD49Q35029019-1DEFE811-48F0-4A4B-AEA7-D8773B3B3911Q35035270-5CE0694A-81B3-4F98-B6CF-1749C5F01225Q35129500-449321D8-FA7A-4028-8082-A2170EBDE8A2Q35266259-3167FAD3-807D-436E-8BC7-23CEDC165A12Q35514622-0198C45E-FD2E-47C0-99B2-31A333AF6372Q35582880-C97E4E2F-5DA4-4205-AFCF-8AA24228D4B9Q35603490-E85107EC-4C6E-4039-8B97-966CDEE90E43Q35747712-CA629F3E-8D1B-4661-98B1-8239597E1D2CQ35763405-EB0FCD88-A565-41B0-AC12-4E3A65B2E7F0Q35813895-C64D771C-6DA1-41EF-A4BF-9AAE648D7614Q36022824-48B47823-1CC3-41C3-8193-21C71E6713FCQ36072299-DE27ACD7-6D6F-43DA-9646-05E6C3B8CAE1Q36094092-1A62BF18-D80A-4C2F-A0B3-DBF185F3FF9EQ36228816-240850D2-5B4A-49F0-8A56-C37613B21147Q36275193-77D45408-92FC-4AA9-AA3B-B68F7E56D8ADQ36424212-1EE53C8B-9970-4E94-8D50-CEC9F508F046Q36506479-B12D6EC6-1765-4E67-816D-FBFA72DE8538Q36671821-94529B57-F71E-4E94-8272-7A78CD9B98E4Q36833723-6B03211D-807F-4290-BD50-A22E51FA1491Q37061089-DF7FA868-5A0B-4304-8341-91EEA788EC6B
P2860
Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Comparison of Xpert MTB/RIF wi ...... e setting: a prospective study
@ast
Comparison of Xpert MTB/RIF wi ...... e setting: a prospective study
@en
Comparison of Xpert MTB/RIF wi ...... e setting: a prospective study
@nl
type
label
Comparison of Xpert MTB/RIF wi ...... e setting: a prospective study
@ast
Comparison of Xpert MTB/RIF wi ...... e setting: a prospective study
@en
Comparison of Xpert MTB/RIF wi ...... e setting: a prospective study
@nl
prefLabel
Comparison of Xpert MTB/RIF wi ...... e setting: a prospective study
@ast
Comparison of Xpert MTB/RIF wi ...... e setting: a prospective study
@en
Comparison of Xpert MTB/RIF wi ...... e setting: a prospective study
@nl
P2093
P2860
P50
P3181
P1433
P1476
Comparison of Xpert MTB/RIF wi ...... e setting: a prospective study
@en
P2093
Adrian Duse
Lesley E Scott
Matilda Nduna
Natasha Gous
Wendy Stevens
Willem F Venter
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1001061
P407
P577
2011-07-01T00:00:00Z